In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Minerva Neurosciences Inc.

www.minervaneurosciences.com

Latest From Minerva Neurosciences Inc.

J&J Leverages Novel Mechanisms In Neuropsychiatry, Neurodegeneration

Janssen Neuroscience therapeutic area head Husseini Manji describes near-, mid- and long-term milestones among J&J's potential blockbusters, including an every six months injection for schizophrenia, Spravato for suicidal ideation, and earlier programs in Alzheimer's disease.

Neurology Research and Development Strategies

J&J Plans 10 Potential Blockbuster Filings By 2023

The company outlined pharma growth drivers, including 14 currently marketed medicines that will achieve $1bn or more in sales by 2020 and 10 new filings through 2023.

Launches Business Strategies

Pipeline Watch: Phase III Top-Line Results With Upadacitinib, Keytruda And Cosentyx

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 


Pipeline Watch Approvals

Pipeline Watch: Phase III Starts For BL-8040, Trigriluzole, MIN-101

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Cyrenaic Pharmaceuticals Inc.
  • Sonkei Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Minerva Neurosciences Inc.
  • Senior Management
  • Remy Luthringer, PhD, Pres., CEO & CSO
    Geoff Race, EVP & CFO
    Joseph Reilly, SVP & COO
    Michael Davidson, MD, CMO
    Jay Saoud, PhD, SVP, Head, R&D
    Justine Lalonde, MD, SVP, Product Strategy
  • Contact Info
  • Minerva Neurosciences Inc.
    Phone: (617) 600-7373
    1601 Trapelo Rd.
    Ste. 284
    Waltham, MA 02451
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register